Overview

Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
BeiGene